Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/199018
Type: Artigo de periódico
Title: Assessment Of Serum Chromogranin-a As Prognostic Factor In High-risk Prostate Cancer.
Author: Reis, Leonardo O
Vieira, Larissa F M
Zani, Emerson L
Denardi, Fernandes
de Oliveira, Laurione C
Ferreira, Ubirajara
Abstract: The presence of neuroendocrine differentiation may play a key role in androgen-independent tumor progression. The prognostic significance of plasma chromogranin-A (CgA) was assessed in a series of consecutive patients with high-risk prostate cancer (PCa). Twenty-three patients presenting high-risk PCa and 8 healthy individuals, as control group, had their blood samples collected to evaluate CgA, free and total prostate specific antigen, and free and total testosterone in a pilot study. The correlations of serum CgA levels with PSA, testosterone, Gleason score, number of foci of hypercaptation in bone scan, age, and outcomes were evaluated at baseline and after 12 months. Patients with PCa had significantly higher levels of plasma CgA (mean, 8.7; range, 1.9-73) than healthy patients (mean, 3.45; range, 0.6-5.6), P = 0.02. Analyzing only the patients group through correlation of the ranks, it was observed that CgA has low, insignificant correlations with PSA (P = 0.07) and with metastatic extension (P = 0.09). No association was found between the plasma CgA levels and the Gleason score (P = 0.20), age (P = 0.15), or disease progression (P = 0.27). The serum levels of CgA were significantly increased in the group with PCa compared with the healthy group. However, there were low correlations between serum CgA and known prognostic factors (such as total and free PSA, age, Gleason score, and bone metastases) or clinical deterioration. Although future studies are needed with larger samples and longer follow-up, the presented data envisage a limited role to serum CgA as high-risk PCa prognostic factor.
Subject: Adenocarcinoma
Aged
Aged, 80 And Over
Chromogranin A
Combined Modality Therapy
Humans
Male
Middle Aged
Pilot Projects
Prognosis
Prostate-specific Antigen
Prostatic Neoplasms
Tumor Markers, Biological
Rights: fechado
Identifier DOI: 10.231/JIM.0b013e3181f5d610
Address: http://www.ncbi.nlm.nih.gov/pubmed/20818262
Date Issue: 2010
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.